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ABSTRACT
Objectives: The routine screening for macroprolactin of all hyperpro-
lactinemic patients may avoid unnecessary imaging procedures and medi-
cation prescription. The study described the frequency and types of tests
requested after a diagnosis of high serum prolactin concentration, and
assessed whether the diagnosis of macroprolactinemia resulted in lower
downstream utilization and costs compared with hyperprolactinemic
patients.
Methods: A cost analysis was conducted using a decision tree to model
the health-care utilization of the two groups. The database of the Fleury
Medicina e Saúde provided the tests and medication of patients with a
prolactin value 30 mg/L for a period of 6 months.
Results: Six hundred ﬁfty-four of 1793 patients (36.5%) had hyperpro-
lactinemia because of macroprolactin. The average number of tests per
individual was higher (P = 0.001) in the patients with true hyperpro-
lactinemia (3.07) than in patients with macroprolactinemia (2.51).The
average cost in the hyperprolactinemic group (R$425 or €162) was sig-
niﬁcantly higher (P < 0.001) than the macroprolactinemic group (R$340
or €130), an incremental cost 25% higher.
Conclusion: The macroprolactin screening did not completely avoid inap-
propriate clinical investigation or associated health-care costs. Our results
demonstrate the importance of proper medical education and knowledge
diffusion of the meaning of macroprolactinemia.
Keywords: costs and cost analysis, health-care costs, hyperprolactinemia,
prolactin.
Introduction
In the majority of individuals, serum human prolactin (PRL)
circulates as a 23-kDa monomer, with small amounts of a
60-kDa form (big PRL) and a high molecular weight of 150 to
170-kDa form, named big-big PRL or macroprolactin, identiﬁed
on gel ﬁltration chromatography [1–3].
The monomer is the predominant form in healthy subjects
and patients with prolactinomas. In contrast, macroprolactin has
been associated with asymptomatic hyperprolactinemia and is
not related to pituitary disease [4–6]. This occurrence appears to
be more common than previously thought, being present in 15%
to 42% of samples from patients with hyperprolactinemia [7–9].
One study revealed that 46% of the patients had hyperpro-
lactinemia because of macroprolactin, but this result is an excep-
tion and is probably biased by the nature of the study center [10].
The need to differentiate between the apparent benign clinical
condition of macroprolactinemia and true hyperprolactinemia,
which requires therapy, is emerging as a concept [11]. Some
authors have recommended that laboratories offering PRL
testing should include the analysis for the presence of macropro-
lactinemia in all cases of elevated PRL results [7–10,12–15].
Although there is an additional cost associated with routine
screening for macroprolactin, substantial savings can be achieved
through diminished requests for imaging procedures and dopam-
ine agonist (DA) prescription, approximately 15% to 17%,
resulting in a net cost beneﬁt [16].
The screening for macroprolactin may not only avoid the
anxiety and suffering of patients that can raise suspicion of a
pituitary tumor after a diagnosis of high PRL, but may also
reduce the adverse effect on health-care costs. These adverse
effects are important, given the large volume of PRL testing,
percentage of misleading diagnoses, inappropriate investigations,
and unnecessary treatment of pseudo-hyperprolactinemic
patients in routine clinical practice. So far, no study has yet
evaluated the follow-up cost of these patients.
Therefore, this study was undertaken to: 1) describe the fre-
quency and types of tests requested after a diagnosis of high
serum PRL concentration; 2) evaluate if the test proﬁle request is
different between the two groups (hyperprolactinemia andmacro-
prolactinemia); and 3) assess whether the diagnosis of macro-
prolactinemia resulted in lower downstream utilization and costs
compared with hyperprolactinemic patients.
Methods
Setting and Sample
From the database of the Fleury Medicina e Saúde (FMS), a
private diagnostic center, we retrieved all the patients that had
performed at least one PRL test (N = 45,958) between January 1,
2004 and April 30, 2007. From those, we identiﬁed 1793 tests
(4%) with a serum PRL value 30 mg/L.
For each of the 1793 tests, the health-care utilization was
assessed for a 6-month follow-up period. Health-care utilization
included hormonal analysis, imaging tests, and medication.
The hormonal analysis included serum PRL, cortisol, lutei-
nizing hormone, follicle-stimulating hormone, estradiol,
progesterone, thyroid-stimulating hormone (TSH), thyroxine,
tri-iodothyronine, free tetra-iodothyronine (FT4), free tri-
iodothyronine (FT3), insulin-like growth factor 1 (IGF1), human
growth hormone, and combined pituitary function test. The
imaging tests included pituitary magnetic resonance imaging
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(MRI), computed tomography scanning (CT), and bone densi-
tometry. The medication included DAs: bromocriptine and
cabergoline.
Approval for this study was obtained from the Ethical
Committee of FMS.
Study Design and Decision Model Structure
A decision tree model for a cost analysis (Fig. 1) was developed
using the TreeAge Pro 2007 software program (TreeAge Software
Inc., Williamstown, MA), and followed economic evaluations
guidelines [17,18].
In our decision tree, the ﬁrst decision node, portrayed as a
square, represents a diagnosis of a serum PRL value 30 mg/L.
The branches of the initial decision node represent the down-
stream health-care utilization of the two groups (hyperpro-
lactinemia and macroprolactinemia) that are to be compared
(Fig. 1).
The cost analysis was performed from the health-care payer
perspective and considered only direct medical costs with hor-
monal analysis, imaging tests, and medication. Because of the
limited time frame, no discount rate was applied to any costs.
A microcosting study was performed to determine the
average cost of the follow-up of a patient in each group (hyper-
prolactinemia and macroprolactinemia). The costs would be













Where, CTH is the sum of all costs of tests and medication
consumed in the hyperprolactinemia group and NH is the number
of individuals in this group. Therefore, the CH represents the
average cost of a follow-up of an individual after a diagnosis of
hyperprolactinemia. The same logic applies to the macro-
prolactinemia group (CM). Costs are presented in 2007 Reals.
Estimates of the frequency and type of tests within each group
were based on the database of FMS. Medications were identiﬁed
also in the database and were informed by the patients during
their visit to the laboratory to perform the tests.
Estimate of tests costs were obtained from the average prices
of tests adopted in FMS in 2007, which represent the private
sector costs.
Medications costs were estimated considering the active
ingredient and dosages recommended in adults and assuming a 6
months treatment period. The unit prices were calculated based
on a monthly, drug-price guide—the ABCFarma, June 2007. For
the bromocriptine, we estimated that a patient would consume
one bottle of bromocriptine 2.5 mg with 28 tabs. Taking two
tabs everyday, two bottles per month would be needed. For the
period of 6 months, 12 bottles would be needed. We estimated
that a patient would consume one bottle of carbergoline 0.5 mg
with eight tabs. Taking one tab every 4 days, it would last about
a month. For the period of 6 months, six bottles would be
needed.
Sensitivity Analysis
A one-way sensitivity analysis was performed for price tests. To
test the impact of lower cost rates, we used prices obtained from
Brazilian Medical Association—the 1999 AMB table, these
prices are practiced by many health-care plans.
Laboratory Methods
Serum PRL was measured by immunoﬂuorometric assay (IFMA,
reference values for adult males 2–10 mg/L, adult females
2–15 mg/L; Delﬁa, Wallac Oy, Turku, Finland). Polyethylene
glycol (PEG) precipitation and/or chromatography were used as
screening methods for the detection and conﬁrmation of macro-
prolactin [9,19].
In summary, to perform PEG precipitation, we added to
250 ml of a patient’s serum, 250 ml of a 250 g/L PEG 6000
solution (in water kept at 4°C), mixed them for 1 minute with a
vortex mixer, centrifuged the mixture for 5 minutes at room
temperature at 9500 g, and determined again the amount of PRL
in the supernatant using the same IFMA and calculating the
recovery on the basis of the original serum value. Recoveries
65% are classiﬁed as predominantly monomeric (hyperpro-
lactinemia), and recoveries of 30% are classiﬁed as predomi-
nantly high molecular weight forms (macroprolactin). Values
between 30% and 65% were classiﬁed as indeterminate and
submitted to chromatography; in this technique, we applied
0.5 ml of patient’s serum in a 0.9 ¥ 30 cm column packed with
Sephacryl S-200 (Pharmacia, Uppsala, Sweden) previously cali-
brated with monomeric 125I PRL (New England Nuclear, Boston,
MA), eluted it with sodium phosphate buffer (0.05 mol/L, pH
7.4), collected 0.7 ml aliquots at 0.1 ml/min, and analyzed the
amount of PRL in these aliquots using the same IFMA [9].
Pituitary Imaging Studies
CT was performed by using a HIspeed CTI scanner (GE Medical
Systems, Milwaukee, WI) with 1-mm slices in the coronal plane
before and after the intravenous (IV) bolus injection of contrast.
MRI was performed by using a GE 1.5-Tesla scanner (GE
Medical Systems), with 1.7- and 2.5-mm slices, and administra-
tion of IV gadolinium was performed to visualize the pituitary in
both saggital and coronal planes.
Statistical Analysis
Comparison of characteristics between true hyperprolactinemic
and macroprolactinemic individuals was performed by the Fisher
exact test or chi-square test for categorical variables, and the
Student unpaired t-test or Mann–Whitney test for continuous
variables. Results are expressed as mean (SD), and statistical
signiﬁcance was set at an a level of 0.05. Statistical analysis was
performed using the software SPSS 15.0 (SPSS Inc., Chicago, IL).
Results
Clinical Data
Of the 45,958 subjects who had taken a PRL test, 1793 (4%) had
a serum PRL value 30 mg/L. Of these, 1793 subjects with
Figure 1 The decision tree model. PRL, prolactin.
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clinically signiﬁcant hyperprolactinemia, 1139 (63.5%; 2.5% of
all patients) were identiﬁed as true hyperprolactinemic and 654
(36.5%) as macroprolactinemic.
Clinical data from the 1793 patients identiﬁed as having
either true hyperprolactinemia or macroprolactinemia are sum-
marized in Table 1. No signiﬁcant difference was found for age,
sex, or PRL values. CT or pituitary MRI was performed in 75
(6.5%) of hyperprolactinemic patients and in 37 (5.6%) of mac-
roprolactinemic patients. Comparing the 3 years (2004–2006),
there was no difference in imaging tests frequency (P = 0.647). In
other words, imaging tests were performed in the same frequency
during this period. Whereas the frequency of scanning did not
differ between the groups, abnormalities were mainly found in
hyperprolactinemic patients (Table 1). The majority of macro-
prolactinemic patients (34 of the 37 patients or 91.9%) presented
normal pituitary images. Microadenomas were diagnosed in two
individuals with macroprolactinemia, but no macroadenoma
was diagnosed in this group.
Seventeen (2.6%) of 654 patients with macroprolactinemia
and 46 (4.0%) of 1139 patients with true hyperprolactinemia
informed that they were being treated with DAs. Comparing the
3 years, there was no difference in DAs prescription (P = 0.628).
In other words, DAs were prescribed in the same frequency in
2004, 2005, and 2006. There was a difference in frequency of
medication treatment between the two groups (P = 0.030), with
more women being treated in the hyperprolactinemia group.
However, there was no difference among those being treated
(P = 0.053).
Comparison of Investigation and Treatment in True
Hyperprolactinemic and Macroprolactinemic Subjects
In both groups, PRL, TSH, and FT4 were the most frequently
requested tests (Table 2). The group of hyperprolactinemic sub-
jects requested a greater quantity of PRL tests (P = 0.039), TSH
(P = 0.003), FT4 (P < 0.010), IGF1 (P = 0.001), and FT3
(P = 0.001).
Regarding the other tests requested, including MRI and CT,
there was no statistically signiﬁcant difference between the
groups (Table 2). The average number of tests per individual was
higher (P = 0.001) in the patients with true hyperprolactinemia
(3.07) than in patients with macroprolactinemia (2.51).
Cost Analysis and Sensitivity Analysis
This retrospective microcosting study included data for 1793
patients. The use of resources and cost associated are described in
Table 3. The group of true hyperprolactinemia performed 3496
tests with a total cost of R$ 425,151 (€162,271) and the mac-
roprolactinemia group performed 1646 tests with a total cost
of R$ 202,917 (€77,449). The total medication costs were
R$59,018 (€22,526) and R$19,621 (€7489) for the hyperpro-
lactinemia and macroprolactinemia groups, respectively.
The average cost per capita to follow-up a true hyperpro-
lactinemic patient (R$425 or €162) was signiﬁcantly higher
(P < 0.001) than the macroprolactinemic group (R$340 or




(n = 654) P-value
Age, years
Mean, SD 41 (12.7) 41.6 (11.4) 0.312*
Median, interquartile range 40 (32–48) 42 (34–49)
Sex n (%)
Male 93 (8.2) 63 (9.6) 0.297†
Female 1045 (91.8) 591 (90.4)
Total prolactin
Mean, SD 71.6 (145.9) 51.6 (29.2) 0.582‡
Median, interquartile range 43 (34–66) 43 (36–56)
CT/MRI performed n = 75 (%) n = 37 (%)
Nonpathologic 35 (46.7) 34 (91.9) <0.001†
Microadenoma 34 (45.3) 2 (5.4) <0.001†
Macroadenoma 6 (8.0) 0 0.072†
Meningioma 0 1 (2.7) 0.149†
DA prescribed n (%) 46 (4.0) 17 (2.6) 0.030†
Cabergoline 30 (65.2) 7 (41.2) 0.053†
Bromocriptine 16 (34.8) 10 (58.8) 0.053†
*P-values for statistical differences (unpaired t-test).
†P-values for statistical differences (Fisher’s exact test).
‡P-values for statistical differences (Mann–Whitney).
CT, pituitary computed tomography scanning; DA, dopamine agonist; MRI, pituitary magnetic resonance imaging; SD, standard deviation.
Table 2 Comparison of the type and number of tests for the hyperpro-






P-valuen N/patient n N/patient
PRL 1187 1.04 630 0.96 0.039
TSH 512 0.45 213 0.32 0.003
FT4 454 0.40 168 0.26 <0.001
FSH 200 0.17 113 0.17 0.401
E2 194 0.17 105 0.16 0.313
LH 180 0.16 100 0.15 0.313
T3 153 0.13 66 0.10 0.222
PROGEST 142 0.12 61 0.09 0.144
T4 104 0.09 48 0.07 0.431
BONEDENSI 68 0.06 34 0.05 0.460
CORT 68 0.06 26 0.04 0.141
IGF1 67 0.06 15 0.02 0.001
MRI 66 0.06 32 0.05 0.554
FT3 53 0.05 13 0.02 0.018
HGH 34 0.03 17 0.03 0.236
CT 12 0.01 5 0.01 0.543
CPFT 2 0.00 0 0.0 0.284
TOTAL 3496 3.07 1646 2.51 0.001
Data are given as number (number of tests per patient), P-values for statistical differences
(c2 test).
BONEDENSI, bone densitometry; CORT, cortisol; CPFT, combined pituitary function test;
CT, computed tomography scanning; E2, estradiol; FSH, follicle-stimulating hormone; FT3, free
tri-iodothyronine;FT4, free tetra-iodothyronine;HGH,human growth hormone; IGF1, insulin-
like growth factor 1; LH, luteinizing hormone; MRI, pituitary magnetic resonance imaging;
PRL, prolactin; PROGEST, progesterone; T3, tri-iodothyronine; T4, thyroxine; TSH, thyroid-
stimulating hormone.
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€130). The incremental cost of the hyperprolactinemic group in
relation to the macroprolactinemic group was around 25%. The
average costs included tests requested and medication prescrip-
tion (Table 4).
A sensitivity analysis is presented in Table 4. In the AMB
scenario, the average costs per capita were R$149 (€57) and
R$109 (€42) for the hyperprolactinemia and macroprolactine-
mia groups. The incremental cost of the hyperprolactinemic
group in relation to the macroprolactinemic group was around
37%.
Discussion
This study showed a prevalence of 36.5% of hyperprolactinemia,
as explained in macroprolactinemia, and this result is similar to
other studies that reported as being present in 15% to 42%
[7–9]. Though this prevalence was lower than one previously
reported in our study center (46%) [10].
Our hypothesis was that with an early detection of the mac-
roprolactin component in hyperprolactinemic sera, no further
investigation would be performed. However, our ﬁndings dem-
onstrate that even after a diagnosis of macroprolactinemia, an
active clinical investigation for pituitary pathology continues,
leading to inappropriate investigation and treatment that
resulted in 1646 tests, prescription of DA to 17 patients, and a
potential needless waste of resources in the magnitude of
R$222,538 (€84,938).
This ﬁgure is very conservative, as we did not take into
account in this analysis: transportation costs, productivity costs
(the time patients allocate to visits to clinic for tests), and the
Table 3 Resource costs used in the cost analysis. In Reals of 2007*
Resource
Tests Unit cost‡ Unit cost†
Hyperprolactinemia Macroprolactinemia
n Total cost¶ Total cost† n Total cost‡ Total cost†
PRL 125.2 24.7 1,187 148,660 29,260 630 78,901 15,530
TSH 93.5 24.7 512 47,857 12,621 213 19,909 5,250
FT4 62.6 24.7 454 28,429 11,191 168 10,520 4,141
FSH 93.5 18.9 200 18,694 3,770 113 10,562 2,130
E2 78.8 29.0 194 15,283 5,626 105 8,272 3,045
LH 101.0 18.9 180 18,180 3,393 100 10,100 1,885
T3 62.6 18.9 153 9,581 2,884 66 4,133 1,244
PROGEST 85.9 30.5 142 12,191 4,324 61 5,237 1,857
T4 62.6 30.5 104 6,512 3,167 48 3,006 1,462
BONEDENSI 259.3 87.0 68 17,631 5,916 34 8,816 2,958
CORT 83.8 21.8 68 5,700 1,479 26 2,180 566
IGF1 140.4 50.0 67 9,406 3,350 15 2,106 750
MRI 1,029.0 308.7 66 67,914 20,374 32 32,928 9,878
FT3 129.3 24.7 53 6,852 1,306 13 1,681 320
HGH 94.4 26.1 34 3,210 887 17 1,605 444
CT 592.5 37.7 12 7,110 452 5 2,963 189
CPFT 970.3 291.1 2 1,941 582 0 0 0
Total 3,496 R$425,151 (€162,271) R$110,583 (€42,207) 1,646 R$202,917 (€77,449) R$51,649 (€19,713)
Medication Unit cost§ n Total cost n Total cost
Cabergoline 1,469 30 44,082 7 10,286
Bromocriptin 933 16 14,936 10 9,335
Total 46 R$59,018 (€22,526) 17 R$19,621 (€7,489)
*2007 Reals (the Brazilian currency, US$ 1 = R$ 1.92, 1 Euro = R$ 2.62).
†Unit price from Brazilian Medical Association—1999 AMB.
‡Unit price from Fleury Medicina e Saúde—FMS.
§Unit price from ABCFarma.
BONEDENSI, bone densitometry; CORT, cortisol; CPFT, combined pituitary function test; CT, computed tomography scanning; E2, estradiol; FSH, follicle-stimulating hormone; FT3, free
tri-iodothyronine; FT4, free tetra-iodothyronine; HGH, human growth hormone; IGF1, insulin-like growth factor 1; LH, luteinizing hormone; MRI, pituitary magnetic resonance imaging;
PRL, prolactin; PROGEST, progesterone;T3, tri-iodothyronine;T4, thyroxine;TSH, thyroid-stimulating hormone.




(n = 654) P-value†
Scenario 1 (FMD prices)
Direct medical costs
Laboratory tests 425,151 202,917
Medication (DA prescription) 59,018 19,621
Total direct cost 484,169 (€184,797) 222,538 (€84,938)
Cost per individual 425 (€162) 340 (€130) <0.001
Scenario 2 (1999 AMB table)
Direct medical costs
Laboratory tests 110,583 51,649
Medication (DA prescription) 59,018 19,621
Total direct cost 169,600 (€64,733) 71,270 (€27,202)
Cost per individual 149 (€57) 109 (€42) 0.006
*Data are given as mean cost in 2007 Reals (the Brazilian currency, US$ 1 = R$ 1.90, 1 Euro = R$ 2.62).
†P-values for statistical differences (Fisher exact test).
AMB, Brazilian Medical Association; DA, dopamine agonist.
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impact in the health-related quality of life of the individual. If we
had adopted the societal perspective and had accounted all these
additional costs, the total cost would signiﬁcantly increase.
We also did not include in our estimate of health resource
utilization of the macroprolactinemia group alternative investi-
gations and treatments for other diagnoses (for example, for
polycystic ovary syndrome, we should have accounted pelvic
ultrasound and other imaging tests) that would have health
resource and cost implications.
There is a lack of literature designed to explore the costs
related to this issue. The only study that speciﬁcally addressed the
cost-effectiveness of routine screening for macroprolactin con-
cluded that the extra ﬁnancial outlay for this procedure was
offset by savings on unnecessary diagnostic imaging and inap-
propriate treatment [16]. The results of the current study, where
a comparison of imaging tests (MRI and CT) frequency between
the groups was carried out, demonstrated no statistically signiﬁ-
cant difference (P = 0.554 and P = 0.543, respectively) (Table 2).
This data indicated that 34 (91.9%) of the imaging procedures
performed in the macroprolactinemic group presented normal
pituitary images, pointing out that the macroprolactin screening
did not avoid these needless procedures. Besides, there were two
cases of microadenomas that probably represent pituitary inci-
dentalomas, and that it would not demand further investigation.
These results raise the question why clinicians are ordering
imaging studies even after a diagnosis of macroprolactinemia.
And these results did not reﬂect a single year. They persisted
through the whole period analyzed. From 2004 to 2006, imaging
tests were performed at the same frequency, suggesting that cli-
nician knowledge did not increase during this period.
To our knowledge, this study is the ﬁrst one to analyze the
cost of follow-up investigation after a raised serum PRL level.
Our study had some limitations. It was retrospective, and
because we only analyzed the database of FMS, we can be sure
that not all the tests were performed in our study center. Some
patients perform some of their tests outside our institution, spe-
cially the imaging tests, because they are not covered by the
health plan. It is possible that we underestimated the total tests
cost. Besides, the medication costs were calculated based on the
referred patient information, and it might be underestimated as
well.
Despite these limitations, our ﬁndings suggest that macropro-
lactin screening had modest effect on overall costs. As seen in
Table 4, the average cost in the hyperprolactinemic group of
R$425 (€162) was signiﬁcantly higher (P < 0.001) than the mac-
roprolactinemic group of R$340 (€130). The difference between
the groups was much smaller than we were expecting to ﬁnd,
with an incremental cost of only 25%.
These results were frustrating, and raised the importance of
correct clinical interpretation of an elevated PRL level. Proper
medical education and knowledge diffusion of the meaning of
macroprolactinemia is mandatory to reduce the wasteful health-
care spending.
Source of ﬁnancial support: This article was prepared without a contract
or funding from a sponsor.
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